Holen Sie sich die Stockscreener-App
90.95
5.53%
-5.32
Vorhandelsmarkt:
90.94
-0.01
-0.01%
Schlusskurs vom Vortag:
$96.27
Offen:
$95.52
24-Stunden-Volumen:
497.18K
Relative Volume:
0.88
Marktkapitalisierung:
$3.80B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-96.76
EPS:
-0.94
Netto-Cashflow:
-
1W Leistung:
-5.17%
1M Leistung:
-8.79%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$90.82
$97.20
1-Wochen-Bereich:
$90.82
$100.40
52-Wochen-Spanne:
$32.00
$117.71
Veradermics Inc Stock (MANE) Company Profile
Firmenname
Veradermics Inc
Sektor
Branche
Telefon
228.372.3376
Adresse
470 JAMES STREET, NEW HAVEN
Compare MANE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
90.95 | 4.02B | 0 | 0 | 0 | -0.94 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veradermics Inc Stock (MANE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-02 | Eingeleitet | Citigroup | Buy |
| 2026-03-02 | Eingeleitet | Jefferies | Buy |
| 2026-03-02 | Eingeleitet | Leerink Partners | Outperform |
Veradermics Inc Aktie (MANE) Neueste Nachrichten
Veradermics Company Profile & Introduction - Moomoo
MANE: Extended-release oral minoxidil shows promise for rapid, consistent hair growth in large, underserved markets - TradingView
Total liabilities of Veradermics, Incorporated – BX:MANE - TradingView
Number of shareholders of Veradermics, Incorporated – BX:MANE - TradingView
Veradermics Incorporated (MANE) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
MANE Technical Analysis | Trend, Signals & Chart Patterns | VERADERMICS INC (NYSE:MANE) - ChartMill
Needham Initiates Veradermics(MANE.US) With Buy Rating, Announces Target Price $136 - Moomoo
This New Hair-Loss Drug Could Be the Biggest Breakthrough in Decades - Cosmopolitan
Veradermics to Present at Upcoming June 2026 Investor Conferences - BioSpace
Veradermics to Present at Upcoming June Investor Conferences - Business Wire
Veradermics to Present VDPHL01 Phase 2/3 ‘302’ Study Results at 2026 World Congress for Hair Research - geneonline.com
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research - BioSpace
Veradermics to present hair loss drug trial data on Friday - Investing.com
Veradermics to present hair loss drug trial data on Friday By Investing.com - Investing.com Canada
New oral drug shows success in reversing hair loss - Fast Company
10 Best Performing NYSE Stocks So Far in 2026 - Insider Monkey
Viking Stake In Veradermics Highlights Risky Growth And Ownership Shifts - Yahoo Finance
Here is Why Veradermics (MANE) is One of the Best Performing NYSE Stocks So Far in 2026 - Insider Monkey
Veradermics Is Maintained at Buy by Citigroup - Moomoo
Veradermics Price Target Raised to $135.00/Share From $120.00 by Citigroup - Moomoo
SR ONE CAPITAL MANAGEMENT, LP's Veradermics Inc(MANE) Holding History - GuruFocus
Citi Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $135 - Moomoo
Viking Global-affiliates hold 1.69M Veradermics shares (MANE) - Stock Titan
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO - Yahoo Finance
Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $138 - Moomoo
Veradermics (MANE) price target increased by 39.48% to 128.52 - MSN
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium - Business Wire
Can Veradermics Rally on Clinical Progress in Biotech Index? - Kalkine Media
Veradermics: Q1 Earnings Snapshot - KTVB
Veradermics 1Q 2026: Revenue ($27.82M), Net income ($30.01M), EPS ($1.32) — 10-Q Summary - TradingView
Veradermics (NYSE: MANE) posts Q1 2026 loss, funding runway into 2030 - Stock Titan
Veradermics Announces Positive Phase 2/3 Results for Oral Hair Loss Treatment VDPHL01, Raises $766.8M to Fund Operations Into 2030 - Minichart
Veradermics: Cash, Cash Equivalents, and Marketable Securities Totaled $390.8M as of March 31 >MANE - Moomoo
New Haven-based drug developer has raised $766.8M so far in ‘26 - Hartford Business Journal
Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - BioSpace
Veradermics (NYSE: MANE) boosts cash with $766.8M raise, advances VDPHL01 - Stock Titan
Earnings Flash (MANE) Veradermics Posts Q1 Net Loss $27.2M, vs. FactSet Est of $22.9M Loss - marketscreener.com
Earnings Flash (MANE) Veradermics Posts Q1 Net Loss $27.2M, Vs. FactSet Est of $22.9M Loss - Moomoo
Veradermics, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MANE SEC FilingsVERADERMICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Veradermics(MANE) Stock Options Chain | Quotes & News - Moomoo
Citi Remains Bullish on Veradermics, Incorporated (MANE) - Yahoo Finance
MANE (Veradermics Incorporated) shares decline 1.75% on widened loss, zero revenue as pipeline costs mount.Interim Report - thelegaladvocate.com
Citadel group reports 1.87M shares in Veradermics (MANE) - Stock Titan
Veradermics prices upsized $384M public offering and $30M private placement at $100/share - MSN
Suvretta-linked funds gain 300,000 MANE pre-funded warrants via awards - Stock Titan
Longitude group discloses 4.65M Veradermics (MANE) shares owned - Stock Titan
Dr. Brian Liu Discloses Investment at Veradermics, Inc with 0.2% Stake - TradingView
Seven Fleet (NASDAQ: MANE) files 13D on Veradermics 0.2% equity stake - Stock Titan
Seven Fleet discloses 80,000 Veradermics (MANE) shares in Form 3 - Stock Titan
Veradermics shares jump 17% on promising hair loss trial results - MSN
Finanzdaten der Veradermics Inc-Aktie (MANE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):